Sunshine Lake Pharma Co Ltd. has divulged non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of multiple sclerosis, psoriasis, rheumatoid arthritis, atopic dermatitis, scleroderma, lupus nephritis, systemic lupus erythematosus and ulcerative colitis, among others.
Onquality Pharmaceuticals China Ltd. has synthesized prodrugs of tofacitinib acting as JAK inhibitors reported to be useful for the treatment of atopic dermatitis, psoriasis and alopecia areata.
Astria Therapeutics Inc. has gained IND clearance from the FDA for STAR-0310, a monoclonal antibody OX40 antagonist being developed for atopic dermatitis.
Discovered and characterized at The University of North Carolina at Chapel Hill, the compound showed potent PDE4D inhibition and demonstrated high selectivity over other PDE families.
Scientists at Institució Catalana de Recerca i Estudis Avançats and Universitat de Barcelona have identified three-prime repair exonuclease 2 (TREX2) inhibitors reported to be useful for the treatment of psoriasis, atopic dermatitis and ichthyosis.
Enanta Pharmaceuticals Inc. has announced the expansion of its immunology portfolio with the nomination of a new development candidate and the introduction of a new discovery program.
Secretome Therapeutics Inc. has closed a $20.4 million round of financing to support its development of therapies derived from neonatal cardiac progenitor cells.
Blood dendritic cell antigen 2 (BDCA2) is expressed in plasmacytoid dendritic cells. These cells’ overproduction of type I interferon is closely linked to the pathogenesis of systemic lupus erythematosus and other autoimmune diseases.
RSS
